Biomarker Profiling for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to study cancer patients by analyzing their blood over time to identify specific DNA markers. Researchers seek to understand how these markers change and their implications for cancer treatment. The trial does not test a new drug; instead, it focuses on gaining a deeper understanding of the disease. Patients with cancer who are willing to provide additional blood samples during regular treatment may be suitable for this study. As an unphased study, this trial offers participants the chance to contribute to groundbreaking research that could enhance cancer understanding and treatment for future patients.
Why are researchers excited about this trial?
Researchers are excited about the TEMPUS ARIES biobank registry platform because it offers a new way to gather and analyze large-scale genomic and clinical data in oncology. Unlike traditional studies that focus on a single treatment or drug, this platform aims to create a comprehensive database that can accelerate the understanding of cancer biology and the development of personalized treatments. By enabling real-time data sharing among researchers, TEMPUS ARIES could lead to more effective and tailored treatment plans, potentially improving patient outcomes faster than current methods.
Who Is on the Research Team?
Michelle Ting-Lin, MD
Principal Investigator
Tempus AI, Inc.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Biomarker Profiling
Participants undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy
Follow-up
Participants are monitored for safety and effectiveness after biomarker profiling
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
Tempus AI
Lead Sponsor